Publications

24.09.25

An Open-Source Framework for Virtual Bioequivalence Modeling and Clinical Trial Design

JournalMethodologyPBPK/PBBMTrial design and analysis

CPT Pharmacometrics Syst Pharmacol. 2025 Sep 24. Online ahead of print.

Hamadeh A, Pellowe M, Chelle P, Yeung CHT, Otalvaro J, Yamada W, Bartroff J, Kryshchenko A, Dallmann A, Solodenko J, Lippert J, Tsakalozou E, Neely M, Edginton A..

30.07.25

Pharmacometrics education for all by overcoming language barriers to enhance global collaboration

Pharmacometrics

J Pharmacokinet Pharmacodyn. 2025 Jul 30;52(4):46.

Khier S, Chan Kwong AHP, Harnichard M, Ait-Oudhia S.

15.06.25

The dawn of a new era: can machine learning and large language models reshape QSP modeling?

AutomationJournalMethodologyQSP

J Pharmacokinet Pharmacodyn. 2025 Jun 16;52(4):36.

Androulakis IP, Cucurull-Sanchez L, Kondic A, Mehta K, Pichardo C, , Pryor M, Renardy M.

03.06.25

Physiologically based predictions of monoclonal antibody pharmacokinetics: insights from a large-scale data analysis

ConferencePBPK/PBBMProgram strategies and efficienciesSpecial considerations

PAGE 33 (2025) Abstr 11791

Benamara S, Sjogren E, Gattacceca F, Chenel M, Deslandes A, Nguyen L, Teutonico D.

03.06.25

Development of efficient CAR-T cell clinical study designs: Towards understanding of novel anticancer therapies through optimal experimental design

ConferenceMethodologyOncologyPharmacometricsTrial design and analysis

PAGE 33 (2025) Abstr 11783

Klima F, Mc Laughlin AM, Michelet R, Winkler A, Huisinga W, Haussmann K, Künkele A, Hooker AC, Kloft C.

Below we provide links to posters, white papers and scientific publications by Pharmetheus affiliates in chronological order. Please note that access to some publications may require a subscription.

Featured Publications

Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection

The reference corrected VPC (rcVPC) – an informative model diagnostics for assessing underying exposure-response relationships

Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption

Search Publications

Publications 5 of 220

Featured Publications

Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection

The reference corrected VPC (rcVPC) – an informative model diagnostics for assessing underying exposure-response relationships

Assessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic Absorption

Search Publications

Publications 5 of 220

Related content

Science and Services

Case studies

Scientific Publication